{"schema_version":"1.0","type":"article","title":"HORIZON：Lp(a) 降了，心梗會少嗎？","url":"https://drugnews.com.tw/articles/2026-07-19-pelacarsen-lpa-horizon.html","markdown_url":"https://drugnews.com.tw/articles/2026-07-19-pelacarsen-lpa-horizon.md","lang":"zh-Hant","date":"2026-07-29","publish_at":"2026-07-29T08:00:00+08:00","updated_at":"2026-07-29","category":"商業分析系列","topic":"商業分析系列","tags":["商業分析系列","Pelacarsen","Lp(a)","HORIZON","心血管疾病","臨床試驗","ASO","Novartis","Ionis","生技投資"],"summary":"Pelacarsen 已證明能大幅降低 Lp(a)，但 HORIZON 真正要回答的是：在標準治療之上，生物標記下降能否轉成更少的心血管死亡、心肌梗塞、中風與緊急再血管化。","key_points":[],"facts":[],"sections":["01｜Lp(a) 為什麼和 LDL-C 不是同一題？","02｜Pelacarsen 已經證明「能降」，還沒證明「能救事件」","03｜HORIZON 的設計，決定我們之後該怎麼讀結果","04｜結果公布時，先別只找「有沒有達標」","05｜為什麼這一讀出會影響整條 Lp(a) 賽道？","06｜台灣讀者最該注意的，不是「有沒有一檔概念股」","最後的主判斷","參考資料"],"references":[{"title":"ClinicalTrials.gov, NCT04023552：","source":"","date":"","url":"https://clinicaltrials.gov/study/NCT04023552"},{"title":"Novartis Q1 2026 investor presentation：","source":"","date":"","url":"https://www.novartis.com/sites/novartis_com/files/q1-2026-investor-presentation.pdf"},{"title":"Ionis Q1 2026 financial results：","source":"","date":"","url":"https://ir.ionis.com/news-releases/news-release-details/ionis-reports-first-quarter-2026-financial-results-and"},{"title":"HORIZON design and rationale, PMID 40185318：","source":"","date":"","url":"https://pubmed.ncbi.nlm.nih.gov/40185318/"},{"title":"Pelacarsen phase 2, PMID 31893580：","source":"","date":"","url":"https://pubmed.ncbi.nlm.nih.gov/31893580/"},{"title":"OCEAN(a)-Outcomes, NCT05581303：","source":"","date":"","url":"https://clinicaltrials.gov/study/NCT05581303"},{"title":"ACCLAIM-Lp(a), NCT06292013：","source":"","date":"","url":"https://clinicaltrials.gov/study/NCT06292013"},{"title":"MOVE-Lp(a), NCT07157774：","source":"","date":"","url":"https://clinicaltrials.gov/study/NCT07157774"}],"images":[{"alt":"HORIZON 真正要驗證的是降低 Lp(a) 能否減少心血管事件，而非只看生物標記下降","url":"https://drugnews.com.tw/assets/articles/pelacarsen-lpa-horizon/facebook-01.webp"},{"alt":"Pelacarsen 從肝臟 LPA mRNA、apo(a) 生成到 Lp(a) 下降的作用鏈，臨床事件端仍待 HORIZON 驗證","url":"https://drugnews.com.tw/assets/articles/pelacarsen-lpa-horizon/facebook-02.webp"},{"alt":"HORIZON 結果應從預設檢定、效果量、事件組成、降幅連結與長期代價五層判讀","url":"https://drugnews.com.tw/assets/articles/pelacarsen-lpa-horizon/facebook-03.webp"},{"alt":"台灣讀者判讀 HORIZON 的四個檢查點：族群、單位、臨床落地與直接證據","url":"https://drugnews.com.tw/assets/articles/pelacarsen-lpa-horizon/facebook-04.webp"}],"cover_image":"https://drugnews.com.tw/assets/articles/pelacarsen-lpa-horizon/cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-07-29）。HORIZON：Lp(a) 降了，心梗會少嗎？。https://drugnews.com.tw/articles/2026-07-19-pelacarsen-lpa-horizon.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-07-19-pelacarsen-lpa-horizon-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}